Tenderwize
Wróć do wyszukiwania

Open House Biologic Discount Agreements 2025-18 - Insulin glargin (100 U/ml)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 367 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-18 - Insulin glargin (Wirkstärke: 100 U/ml)

40/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

60 / 100

Czynniki ryzyka

The procedure is not a public procurement subject to procurement review; disputes go to social courts. Legal recourse i...

No estimated value – potential revenue is unknown. Contract may attract many participants, diluting volume.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Execution of a discount agreement (Rabattvertrag) for Insulin glargin (100 U/ml) with participating health insurance funds.
  • Supply of the pharmaceutical product under standardized conditions for up to 24 months.
Pokaż pełne podsumowanie

This is an Open-House procedure for pharmaceutical discount agreements (Rabattverträge) on Insulin glargin (100 U/ml) with multiple German statutory health insurance funds led by Techniker Krankenkasse. The procedure is open to all qualified pharmaceutical entrepreneurs who meet the eligibility criteria. The contract term is up to 24 months starting from 1 September 2025 (with a later start for hkk on 1 October 2025) and ending no later than 31 August 2027. No estimated value is provided. The award is based solely on meeting eligibility requirements, not on competition. Electronic submission is not allowed via the portal; contracts must be submitted by email (with qualified electronic signature) or by post.

Ryzyka

The procedure is not a public procurement subject to procurement review; disputes go to social courts. Legal recourse i...

No estimated value – potential revenue is unknown. Contract may attract many participants, diluting volume.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product in Germany or be entitled to place it on the market under own name.
  • Seat must be in Germany, another EU member state, or an EEA state.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Biologic Discount Agreements 2025-18 - Insulin glargin (100 U/ml)

Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Insulin glargin (Wirkstärke: 100 U/ml) im Rahmen eines Open-House-Verfahrens. The lot covers nationwide supply of Insulin glargin with a maximum contract duration of 24 months.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Termin

Deadline Aug 30, 2027

Szczegóły zamówienia

Data publikacji
09 Jun 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
372143-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30